Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Ovarian news from ESMO 2018: SOLO-1 results for olaparib

Kathleen Moore • 21 Oct 2018
ESMO 2018
Gynecological Cancer Ovarian Cancer Olaparib
SOLO-1

Ovarian cancer research is moving forwards, as displayed at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Kathleen Moore, MD, MS, of the Stephenson Cancer Center, Oklahoma City, OK, gave an update on the SOLO-1 trial (NCT01844986) of olaparib maintenance monotherapy for BRCA-mutated ovarian cancer after first-line platinum-based chemotherapy.

More from Kathleen Moore

5:03
FORWARD I: mirvetuximab soravtansine vs chemo in platinum-resistant ovarian cancer
Kathleen Moore • 29 Sep 2019
3:45
PARP inhibitors for ovarian cancer
Kathleen Moore • 30 Sep 2019
3:58
SOLO-1: practice changing data on olaparib for ovarian cancer
Kathleen Moore • 19 Oct 2018
2:27
The PAOLA-1 study: olaparib and bevacizumab for ovarian cancer
Kathleen Moore • 19 Oct 2018

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals